Abstract:Importance Although IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, there is no validated tool to predict disease progression. This limits patient-specific risk stratification and treatment decisions, clinical trial recruitment, and biomarker validation. Objective To derive and externally validate a prediction model for disease progression in IgAN that can be applied at the time of kidney biopsy in multiple ethnic groups worldwide. Design, Setting, and Participants We derived and externally validated a prediction model using clinical and histologic risk factors that are readily available in clinical practice. Large, multi-ethnic cohorts of adults with biopsy-proven IgAN were included from Europe, North America, China, and Japan. Main Outcomes and Measures Cox proportional hazards models were used to analyze the risk of a 50% decline in estimated glomerular filtration rate (eGFR) or end-stage kidney disease, and were evaluated using theR2Dmeasure, Akaike information criterion (AIC), C statistic, continuous net reclassification improvement (NRI), integrated discrimination improvement (IDI), and calibration plots. Results The study included 3927 patients; mean age, 35.4 (interquartile range, 28.0-45.4) years; and 2173 (55.3%) were men. The following prediction models were created in a derivation cohort of 2781 patients: a clinical model that included eGFR, blood pressure, and proteinuria at biopsy; and 2 full models that also contained the MEST histologic score, age, medication use, and either racial/ethnic characteristics (white, Japanese, or Chinese) or no racial/ethnic characteristics, to allow application in other ethnic groups. Compared with the clinical model, the full models with and without race/ethnicity had betterR2D(26.3% and 25.3%, respectively, vs 20.3%) and AIC (6338 and 6379, respectively, vs 6485), significant increases in C statistic from 0.78 to 0.82 and 0.81, respectively (ΔC, 0.04; 95% CI, 0.03-0.04 and ΔC, 0.03; 95% CI, 0.02-0.03, respectively), and significant improvement in reclassification as assessed by the NRI (0.18; 95% CI, 0.07-0.29 and 0.51; 95% CI, 0.39-0.62, respectively) and IDI (0.07; 95% CI, 0.06-0.08 and 0.06; 95% CI, 0.05-0.06, respectively). External validation was performed in a cohort of 1146 patients. For both full models, the C statistics (0.82; 95% CI, 0.81-0.83 with race/ethnicity; 0.81; 95% CI, 0.80-0.82 without race/ethnicity) andR2D(both 35.3%) were similar or better than in the validation cohort, with excellent calibration. Conclusions and Relevance In this study, the 2 full prediction models were shown to be accurate and validated methods for predicting disease progression and patient risk stratification in IgAN in multi-ethnic cohorts, with additional applications to clinical trial design and biomarker research.

An enhanced machine learning approach for effective prediction of IgA nephropathy patients with severe proteinuria based on clinical data

Integrated Proteomics and Metabolomics to Study IgA Nephropathy on Early Stage and Identification of Biomarkers

Machine learning-based diagnosis and prognosis of IgAN: A systematic review and meta-analysis

Machine learning-based diagnostic prediction of IgA nephropathy: model development and validation study

Patient classification and outcome prediction in IgA nephropathy

IgA Nephropathy Prediction in Children with Machine Learning Algorithms

Prediction of prognosis in immunoglobulin a nephropathy patients with focal crescent by machine learning

An Interpretable Machine Learning Survival Model for Predicting Long-term Kidney Outcomes in IgA Nephropathy.

Prediction and Risk Stratification of Kidney Outcomes in IgA Nephropathy.

Machine learning in predicting <i>T</i>-score in the Oxford classification system of IgA nephropathy

Establishment and validation of diagnostic model in immunoglobulin A nephropathy based on weighted gene co-expression network analysis

Urinary Proteome Analysis by Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry with Magnetic Beads for Identifying the Pathologic Presentation of Clinical Early Iga Nephropathy

Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy

A Multicenter Application and Evaluation of the Oxford Classification of IgA Nephropathy in Adult Chinese Patients

Machine learning in predicting T-score in the Oxford classification system of IgA nephropathy

Evaluating a New International Risk-Prediction Tool in IgA Nephropathy

Unveiling biomarkers and therapeutic targets in IgA nephropathy through large-scale blood transcriptome analysis

Predicting Progression Of Iga Nephropathy: New Clinical Progression Risk Score

Personalized Decision Support System for Tailoring IgA Nephropathy Treatment Strategies

Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients.

Identifying potential biomarkers for the diagnosis and treatment of IgA nephropathy based on bioinformatics analysis